Details of Disease

General Information of Disease (ID: DISWDJNU)

• Disease Name: MRSA infection
• Disease Class: 1D01: Infectious meningitis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISWDJNU: MRSA infection
• ICD Code:
  ICD-11: ICD-11: 1D01.0Y
  ICD-10: ICD-10: A49.02
  ICD-9: ICD-9: 41.12
  Expand ICD-9: 41.12

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[1]
Vancomycin	DM3JFIH	Approved	NA	[2]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Contezolid	DMZ0F65	Phase 2	NA	[3]
WCK-2349	DMH6XJG	Phase 2	NA	[4]
AZD-9742	DMIKPU4	Phase 1	NA	[5]
TXA709	DMZIK8R	Phase 1	Small interfering RNA	[6]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ETX-1153a	DMT2OWY	Preclinical	NA	[7]
ETX-1153b	DMF6EON	Preclinical	NA	[7]

This Disease is Treated as An Indication in 5 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AKB-4924	DMA756P	Investigative	NA	[2]
EDP-MRSA-1	DMFX7EG	Investigative	NA	[2]
Sharon-5000	DMYKD3S	Investigative	NA	[2]
SLP-1003	DMMWU4H	Investigative	NA	[2]
StaphStop	DMZL3DK	Investigative	NA	[2]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis. 2011 Jun;52 Suppl 7:S513-9.
• [2] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [3] MICURX PHARMACEUTICALS COMPLETES PHASE 1 TRIAL FOR MRX-I, A NEXT-GENERATION ANTIBIOTIC. Micurx pharmaceuticals.
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038027)
• [5] ClinicalTrials.gov (NCT01030224) This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects. U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of TAXIS Pharmaceuticals.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025614)